Profile data is unavailable for this security.
About the company
Shanghai Fosun Pharmaceutical Group Co Ltd is a China-based company mainly engaged in the research and development, manufacturing and sales of pharmaceutical products. The Company operates in five segments. Pharmaceutical segment is mainly engaged in the manufacturing of innovative drugs, mature pharmaceutical products and vaccines. Medical Devices and Medical Diagnostics segment is mainly engaged in the manufacturing and sales of medical cosmetic devices such as molecular diagnosis, immunodiagnosis, and microbial diagnosis. Medical Health Services segment is mainly engaged in the operation of an online and offline integrated medical service platform. Pharmaceutical Distribution and Retail segment is mainly engaged in the wholesale and retail of pharmaceutical products. Others segment is engaged in other pharmaceutical-related businesses. The Company's products are mainly used in the treatment of tumors, immunity, central nervous system and other fields.
- Revenue in CNY (TTM)40.69bn
- Net income in CNY2.01bn
- Incorporated1995
- Employees40.37k
- LocationShanghai Fosun Pharmaceutical Group Co LtdBuilding A, No. 1289 Yishan RoadSHANGHAI 200233ChinaCHN
- Phone+86 2 133987870
- Fax+86 2 133987871
- Websitehttps://www.fosunpharma.com/
More ▼
Mergers & acquisitions
| Acquired company | 600196:SHH since announced | Transaction value |
|---|---|---|
| Shanghai Rehabilitation Equity Investment Fund Management Co Ltd | -20.51% | 3.04m |
| Suzhou Xingchen Venture Capital Partnership LP | -27.30% | 412.00k |
| Shining Star (Tianjin) Investment Management Partnership LP | -27.30% | 206.00k |
Data delayed at least 15 minutes, as of Jul 05 2024.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kangmei Pharmaceutical Co Ltd | 4.93bn | 160.40m | 29.39bn | 4.41k | 182.29 | 4.14 | -- | 5.96 | 0.0116 | 0.0116 | 0.3577 | 0.5117 | 0.34 | 1.40 | 2.43 | 1,118,464.00 | 1.12 | -17.60 | 1.69 | -32.24 | 22.71 | -72.78 | 3.28 | -101.19 | 0.8746 | -- | 0.0465 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
| Hubei Jumpcan Pharmaceutical Co Ltd | 9.67bn | 2.99bn | 29.73bn | 5.23k | 9.89 | 2.08 | -- | 3.07 | 3.26 | 3.26 | 10.54 | 15.51 | 0.5504 | 3.66 | 4.60 | 1,848,716.00 | 17.05 | 16.23 | 22.52 | 20.88 | 79.76 | 82.64 | 30.98 | 24.42 | 3.01 | -- | 0.1275 | 41.76 | 7.32 | 6.02 | 30.04 | 10.83 | -14.70 | 1.11 |
| Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 8.15bn | 973.25m | 30.27bn | 4.62k | 24.82 | 3.46 | -- | 3.71 | 1.27 | 1.27 | 10.60 | 9.09 | 0.744 | 3.12 | 3.24 | 1,765,208.00 | 8.71 | 8.96 | 13.06 | 12.80 | 43.68 | 40.82 | 11.70 | 10.67 | 1.62 | -- | 0.1381 | 56.93 | -0.3266 | 5.28 | 14.49 | 11.93 | -4.33 | 42.22 |
| Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 76.83bn | 4.11bn | 44.93bn | 28.05k | 11.47 | 1.28 | -- | 0.5848 | 2.52 | 2.52 | 47.25 | 22.68 | 1.01 | 6.70 | 4.70 | 2,739,343.00 | 5.67 | 5.90 | 10.56 | 12.40 | 18.07 | 18.70 | 5.63 | 5.56 | 1.35 | -- | 0.3132 | 30.02 | 6.68 | 12.32 | 2.25 | 3.34 | 27.75 | 12.05 |
| Beijing Tiantan Biological Products Corp | 5.11bn | 1.16bn | 45.78bn | 4.86k | 32.75 | 3.76 | -- | 8.96 | 0.7068 | 0.7068 | 3.10 | 6.15 | 0.3611 | 0.9104 | 171.46 | 1,051,960.00 | 11.18 | 11.71 | 16.00 | 16.50 | 52.26 | 49.39 | 30.97 | 27.71 | 3.41 | -- | 0.0094 | 16.67 | 21.57 | 12.06 | 25.99 | 16.85 | 29.67 | 33.99 |
| Beijing Tongrentang Co Ltd | 17.99bn | 1.72bn | 52.20bn | 16.78k | 30.32 | 3.84 | -- | 2.90 | 1.26 | 1.26 | 13.11 | 9.90 | 0.6079 | 1.23 | 10.82 | 1,072,010.00 | 8.84 | 8.20 | 16.50 | 16.17 | 45.32 | 46.59 | 14.55 | 13.33 | 2.28 | -- | 0.1632 | 30.93 | 16.19 | 4.68 | 16.92 | 8.03 | -12.01 | 13.97 |
| Shanghai Fosun Pharmaceutical (Group) | 40.69bn | 2.01bn | 52.84bn | 40.37k | 28.85 | 1.25 | -- | 1.30 | 0.7525 | 0.7525 | 15.24 | 17.36 | 0.368 | 2.90 | 5.28 | 1,007,829.00 | 2.32 | 4.31 | 3.83 | 7.01 | 46.73 | 50.71 | 6.31 | 10.65 | 0.79 | -- | 0.3818 | 31.92 | -5.81 | 10.69 | -36.04 | -2.50 | 10.95 | -3.34 |
| Sichuan Biokin Pharmaceutical Co Ltd | 5.90bn | 4.39bn | 70.34bn | 2.09k | 16.02 | 13.64 | -- | 11.92 | 10.95 | 10.95 | 14.71 | 12.86 | 1.37 | 1.85 | 41.29 | 2,828,652.00 | 102.16 | -- | 138.88 | -- | 95.70 | -- | 74.42 | -- | 3.75 | 828.87 | 0.1314 | -- | -20.11 | -- | -176.40 | -- | -- | -- |
Data as of Jul 05 2024. Currency figures normalised to Shanghai Fosun Pharmaceutical Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
8.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perseverance Asset Management LPas of 30 Jan 2023 | 47.62m | 2.25% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 25.43m | 1.20% |
| China Merchants Fund Management Co., Ltd.as of 30 Sep 2023 | 24.93m | 1.18% |
| UBS Asset Management Switzerland AGas of 30 Jan 2023 | 20.10m | 0.95% |
| Caitong Fund Management Co., Ltd.as of 30 Jan 2023 | 13.57m | 0.64% |
| China Asset Management Co., Ltd.as of 30 Sep 2023 | 12.14m | 0.57% |
| Yinhua Fund Management Co., Ltd.as of 30 Sep 2023 | 10.52m | 0.50% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 9.15m | 0.43% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 9.06m | 0.43% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Sep 2023 | 8.16m | 0.39% |
More ▼
Data from 31 Dec 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
